Metabolic Syndrome Market

Market Overview:

The 7 major metabolic syndrome markets reached a value of USD 53.4 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 115.2 Billion by 2035 exhibiting a growth rate (CAGR) of 7.30% during 2025-2035.

The metabolic syndrome market has been comprehensively analyzed in IMARC's new report titled "Metabolic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Metabolic syndrome is a collection of diseases that cause an increased risk of heart disease, stroke, and type 2 diabetes. They consist of hypertension, hyperglycemia, increased abdominal fat, and hypercholesterolemia or hypertriglyceridemia. The patients with this condition have a 2-fold higher risk of atherosclerotic cardiovascular diseases and a 5-fold greater risk of diabetes mellitus, compared to the general population. Certain individuals may develop greater thirst, urination, weakness, blurred vision, and poor concentration. Furthermore, dark, velvety spots on the neck or armpits may develop as a result of insulin resistance. Metabolic syndrome is diagnosed when an individual has three or more of the following: a large waistline, high triglycerides, low HDL cholesterol, high blood pressure, and high fasting blood sugar. A healthcare provider may assess these parameters by blood tests, blood pressure measures, and a physical examination, which involves measuring waist circumference. Furthermore, a comprehensive metabolic panel can provide an overall view of the patient's health by measuring various substances in the blood, including glucose, cholesterol, and electrolytes.

The escalating cases of obesity, in which fat cells release chemicals that can lead to insulin resistance and other metabolic problems, are primarily driving the metabolic syndrome market. In addition to this, the increasing utilization of effective medications, such as ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, beta-blockers, etc., to help lower blood pressure, is also creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications, including healthy eating, regular physical activity, and maintaining a healthy weight for managing and preventing metabolic syndrome, is further bolstering the market growth. These changes can help improve insulin sensitivity, reduce blood pressure, and lower triglyceride levels in patients. Apart from this, the rising usage of physiotherapy on account of its several benefits, like boosted metabolism, increased muscle mass, and improved overall fitness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of inulin-coated medium-chain triglyceride (InuMCT) microcapsules, since they are designed to reduce inflammation and improve metabolic markers, such as blood glucose levels, is expected to drive the metabolic syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the metabolic syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for metabolic syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metabolic syndrome market in any manner.

Recent Developments:

• In February 2025, Novo Nordisk stated that the U.S. Food and Drug Administration (FDA) had determined that the Wegovy and Ozempic shortages had been resolved. The FDA's assessment showed that the supply of prescription-only GLP-1 medications in the United States now meets or exceeds both current and projected demand.
• In August 2024, Clearmind Medicine Inc. stated that the new research published by Baraghithy et al. indicated promising findings from a recent study on 5-methoxy-2-aminoindane (MEAI) for obesity treatment. The results showed that MEAI considerably improved glycemic control by lowering hyperglycemia, glucose intolerance, and hyperinsulinemia, indicating its therapeutic potential in controlling glucose metabolism.

Drugs:

Wegovy (semaglutide) works by mimicking the hormone GLP-1 (glucagon-like peptide-1), which regulates appetite and glucose metabolism. It enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes a feeling of fullness, helping reduce caloric intake. For individuals with metabolic syndrome, this leads to weight loss, improved insulin sensitivity, better blood sugar control, and reductions in blood pressure and lipid levels, addressing multiple syndrome components simultaneously.

Saxenda (liraglutide) is a GLP-1 analog used to treat type 2 diabetes mellitus, prevent diabetes-related cardiovascular problems, and control obesity. Liraglutide is an agonist of the glucagon-like peptide-1 receptor, which is linked to adenylate cyclase. The rise in cyclic AMP increases the glucose-dependent release of insulin, inhibits the glucose-dependent release of glucagon, and slows stomach emptying to improve blood sugar control.

Qsymia (phentermine and topiramate extended-release capsules) works by decreasing hunger and increasing satiety, resulting in weight loss. Phentermine, a sympathomimetic drug, reduces appetite by activating the sympathetic nervous system and boosting noradrenaline production in the brain. Topiramate, an antiepileptic medicine, may also help with weight loss by lowering caloric intake and maybe increasing satiety.

Xenical (orlistat) is a potent and selective inhibitor of a variety of lipase enzymes involved in fat metabolism. It works in the gastrointestinal (GI) tract by covalently binding to serine residues on the active sites of gastric and pancreatic lipases. When taken with fat-containing foods, orlistat partially inhibits triglyceride hydrolysis. This reduces the absorption of monoacylglycerides and free fatty acids, which aids in weight maintenance and loss.

5-Methoxy 2-aminoindane (MEAI) is a psychoactive chemical hypothesized to work primarily via modulating serotonin and dopamine neurotransmission. It targets components involved in reward, impulse control, and satiety. MEAI aims to minimize compulsive behaviors associated with metabolic syndrome, such as overeating and excessive alcohol intake, both of which contribute to obesity and metabolic dysfunction.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the metabolic syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the metabolic syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current metabolic syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report.

Market Insights

• How has the metabolic syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the metabolic syndrome across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the metabolic syndrome across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of metabolic syndrome across the seven major markets?
• What is the number of prevalent cases (2019-2035) of metabolic syndrome by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of metabolic syndrome by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with metabolic syndrome across the seven major markets?
• What is the size of the metabolic syndrome patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of metabolic syndrome?
• What will be the growth rate of patients across the seven major markets?

Metabolic Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for metabolic syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metabolic syndrome market?
• What are the key regulatory events related to the metabolic syndrome market?
• What is the structure of clinical trial landscape by status related to the metabolic syndrome market?
• What is the structure of clinical trial landscape by phase related to the metabolic syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the metabolic syndrome market?